Australian Bat Lyssavirus: examination of post-exposure treatment in NSW
Ben Ewald A C and David Durrheim BA Newcastle University, New South Wales
B Hunter New England Population Health, Hunter New England Area Health Service
C Corresponding author. Email: ben.ewald@newcastle.edu.au
NSW Public Health Bulletin 19(6) 104-107 https://doi.org/10.1071/NB07050
Published: 26 June 2008
Abstract
Ten years after the recognition of Australian Bat Lyssavirus, it is timely to review the occurrence of the virus in native microbat and flying fox species in Australia, and the effectiveness of post-exposure treatment in humans. Differences between post-exposure treatment protocols adopted by state and territory health departments were examined. In Queensland and the United States of America, post-exposure treatment is withheld in people who are bitten by bats that subsequently test negative for ABLV and rabies, respectively. The good outcomes from these protocols support the revised NSW policy, which delays post-exposure treatment for up to 48 hours for minor exposures while awaiting bat test results. Post-exposure treatment can be withheld or ceased if the bat test result is negative.
Acknowledgements
We are grateful to NSW Department of Primary Industry and Queensland Health scientific services staff who provided the data for Table 1, staff from AAHL who provided the details on the diagnostic methods, and from PHUs in all Australian states and territories who provided copies of their public health protocols.
[1] Hooper P, Lunt R, Gould A, Samaratunga H, Hyatt A, Gleeson L, et al. A new Lyssavirus: the first endemic rabies related virus recognised in Australia. Bull Inst Pasteur 1997; 95 209–18.
| Crossref | GoogleScholarGoogle Scholar |
[2] Gould AR, Hyatt A, Lunt R, Kattenhelt J, Hengstberger S. Characterisation of a novel lyssavirus isolated from Pteropid bats in Australia. Virus Res 1998; 54 165–87.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[3] Fraser G, Hooper P, Lunt R, Gould A, Gleeson L, Hyatt A. Encephalitis caused by a lyssavirus in fruit bats in Australia. Emerg Infect Dis 1996; 2 327–31.
| PubMed |
[4] Hanna J, Carney I, Smith G, Tannenberg A, Deverill J, Botha J, et al. Australian bat lyssavirus infection: a second human case, with long incubation period. Med J Aust 2000; 172 597–9.
| PubMed |
[5]
[6]
[7]
[8] Young M, McCall B. Trends in potential exposure to Australian bat Lyssavirus in south east Queensland, 1996 to 2003. Commun Dis Intell 2004; 28 258–60.
| PubMed |
[9] Warrilow D, Harrower B, Smith I, Field H, Taylor R, Walker C, et al. Public health surveillance for ABLV in Queensland, Australia 2000, 2001. Emerg Infect Dis 2003; 9 262–4.
| PubMed |
[10] Rupprecht C, Gibbons R. Prophylaxis against rabies. N Engl J Med 2004; 351 2626–35.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[11] Jackson A, Warrell M, Rupprecht C. Management of rabies in humans. Clin Infect Dis 2003; 36 60–3.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[12] Cleaveland S, Fevre EM, Kaare M, Coleman PG. Estimating human rabies mortality in the United Republic of Tanzania from dog bite injuries. Bull World Health Organ 2002; 80 304–10.
| PubMed |
[13] Brookes S, Parsons G, Johnson N, McElhinney L, Fooks A. Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune response against European and Australian bat lyssaviruses. Vaccine 2005; 23 4101–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[14]
[15]
[16] Wilde H, Choomkasien P. Failure of rabies postexposure treatment in Thailand. Vaccine 1989; 7 49–52.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[17] Wilde H, Sirikawin S. Failure of postexposure treatment of rabies in children. Clin Infect Dis 1996; 22 228–32.
| PubMed |
[18]
